TOG Review (RCOG Journal)

MRCOG Part 2

Antenatal Care

The role of antenatal corticosteroids in improving neonatal outcomes

Key Statistics

  • 24+0–33+6 weeks — Single-course ACS window (WHO/NICE/ACOG)
  • 0.66 — RR RDS, ACS vs none (Cochrane, 30 trials)
  • 18–36h — Optimal ACS-to-delivery interval for max benefit

Don't-miss facts

  1. ACS benefit is time-limited: only clear benefit if delivery occurs within 7 days of administration – accurate prediction of preterm birth risk is essential

  2. Standard course: betamethasone 12 mg IM ×2, 24h apart OR dexamethasone 6 mg IM ×4, 12h apart; single course 24+0–33+6 weeks (WHO/NICE/ACOG)

  3. Greatest mortality benefit if given 18–36 hours pre-delivery; >7 days before delivery linked to a 40% relative ↑ in mortality vs the 1–7 day window

  4. NICE: do not routinely repeat ACS courses; ACOG/WHO allow a single rescue course if still high risk and ≥7–14 days from last course

  5. Repeat ACS courses consistently ↓birthweight/growth (ACTORDS, MACS, NICHD); MACS 5-year data show repeat- exposed infants born at term have ↑death/disability (OR 1.69) and ↑neurosensory disability (OR 3.70)

  6. ALPS trial (late preterm 34+0–36+5 weeks): ACS ↓respiratory morbidity but ↑neonatal hypoglycaemia (24.0% vs 15.0%)

  7. ACT trial in LMIC: ACS associated with ↑28-day mortality (RR 1.12) in the whole study population – high-income evidence of benefit does not automatically apply to LMIC settings

  8. Cochrane review of elective term CS: ACS ↓RDS by 52% and ↓TTN by 57%, but all 4 trials at risk of bias – interpret with caution

Trial name quick-reference

ACTORDS – repeat q7d, ↓RDS/oxygen need, ↓birthweight

MACS – repeat q14d, no morbidity benefit, ↓growth, term subgroup harm at 5y

NICHD – repeat q7d (max 4), stopped early for safety/growth concerns ALPS – late preterm, ↓resp. support but ↑hypoglycaemia

ASTECS – elective term CS, ↓RDS admissions but small absolute numbers ACT – LMIC, ↑overall mortality in whole population

Abbreviation Key

  • ACS — antenatal corticosteroids
  • WHO — World Health Organization
  • RDS — respiratory distress syndrome
  • 11β-HSD2 — 11β-hydroxysteroid dehydrogenase type 2
  • NEC — necrotising enterocolitis
  • GR — glucocorticoid receptor
  • IVH — intraventricular haemorrhage
  • HPA — hypothalamic–pituitary axis
  • PVL — periventricular leukomalacia
  • fFN — fetal fibronectin
  • BPD — bronchopulmonary dysplasia
  • AUROC — area under the receiver operating characteristic curve
  • TTN — transient tachypnoea of the newborn
  • RCT — randomised controlled trial
  • PPROM — preterm prelabour rupture of membranes
  • RR — relative risk
  • NICE — National Institute for Health and Care Excellence
  • OR — odds ratio
  • ACOG — American College of Obstetricians and Gynecologists
  • HR — hazard ratio
  • CI — confidence interval
  • ALPS — Antenatal Late Preterm Steroids trial
  • MACS — Multiple Courses of Antenatal Corticosteroids for Preterm
  • ASTECS — Antenatal Steroids for Term Caesarean Section trial Birth trial
  • ASTEROID — betamethasone vs dexamethasone RCT
  • ACTORDS — Australasian Collaborative Trial of Repeat Doses of
  • ACT — Antenatal Corticosteroids Trial (LMIC cluster RCT) Steroids
  • LMIC — low- and middle-income countries
  • NICHD — National Institute of Child Health and Human Development study

Source: Busuulwa P et al. The role of antenatal corticosteroids in improving neonatal outcomes. The Obstetrician & Gynaecologist 2021;23:246–257. doi:10.1111/tog.12768

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free